Background: Programmed cell death ligand 1 (PD-L1) is a cell surface molecule that plays a critical role in suppressing immune responses, mainly through binding of the PD-1 receptor on T lymphocytes. PD-L1 may be expressed by metastatic melanoma (MM). However, its clinical and biological significance remains unclear. Here, we investigated whether expression of PD-L1 in MM identifies a biologically more aggressive form of the disease, carrying prognostic relevance.
introduction
In its early-stages melanoma can be cured by surgical resection, but once it progresses to the metastatic stage it remains an incurable disease [1] . The finding of somatic mutations in the BRAF oncogene in ∼40%-50% of melanoma patients [2, 3] paved the way to the introduction of BRAF inhibitors (BRAFi) as a standard treatment in locally advanced or metastatic melanoma (MM) patients (MMP) with BRAF V600 mutation [4] . While clinical responses to BRAFi may be dramatic and some patients treated with BRAF and MEK inhibitors (MEKi) may stay in remission for years, the median duration of response is 7 months for patients treated with BRAFi alone and 11 months for patients treated with BRAFi and MEKi. For this reason, there is intense investigation into alternative or complementary therapeutic strategies, including novel immunomodulatory agents. Among these drugs, anti-PD-1 and anti-programmed cell death ligand 1 (PD-L1)-directed therapies show significant clinical promises [5] [6] [7] . PD-L1/CD274 is one of the two ligands for the T-cell inhibitory receptor PD-1 [8] . It may be expressed on different cell types, including hematopoietic and epithelial cells, and is upregulated in response to proinflammatory cytokines, such as IFN-γ and IL-4 [9] . It may also be expressed by tumor cells, as well as by non-neoplastic elements in the tumor microenvironment [10] [11] [12] . In agreement with the proposed function of the PD-1/PD-L1 axis in the induction and maintenance of peripheral tolerance [11] , surface expression of PD-L1 in some tumors has been reported to be an independent predictor of adverse clinical outcome [13] . Furthermore, expression of the molecule appears to correlate with response to treatment, at least in some tumor models [12] .
In MM, PD-L1 + cells co-localize with tumor-infiltrating lymphocytes and IFN-γ production, suggesting that expression of this molecule is part of the resistance strategy orchestrated by the tumor against the host immune response [12] . However, the prognostic significance of PD-L1 expression in melanoma remains incompletely explored [14, 15] .
By using qRT-PCR and immunohistochemistry, PD-L1 expression was evaluated in a longitudinal cohort of MMP. The finding of a negative prognostic role for PD-L1 is backed by in vitro data showing that the PD-L1 + fraction of the A375 melanoma cell line may be considered distinctly a more aggressive disease genetically, morphologically and phenotypically.
materials and methods

patient characteristics
Cohort characteristics are reported in supplementary Materials and Methods, available at Annals of Oncology online (Immunohistochemistry (IHC), DNA extraction from formalin-fixed paraffin-embedded tissues (FFPE), B-RAF mutation detection, mRNA extraction and detection by quantitative and real time PCR). Detailed protocols are reported in supplementary Materials and Methods, available at Annals of Oncology online.
cells and reagents
The cell lines and the antibodies used for this work are detailed in supplementary Materials and Methods, available at Annals of Oncology online.
Induction of PD-L1/CD274 expression by lentiviral technology, flow cytometry, western blot, confocal microscopy and in vitro assays.
Detailed protocols are reported in supplementary Materials and Methods, available at Annals of Oncology online .
gene expression profiling and analysis RNA extraction, labeling and analysis were carried out as detailed in supplementary Materials and Methods, available at Annals of Oncology online.
xenograft models Xenograft models are described in supplementary Materials and Methods, available at Annals of Oncology online.
statistical analysis
Disease-free survival (DFS) was calculated as the time from first melanoma diagnosis to first recurrence or death. Overall survival (OS) was calculated as the time from first melanoma diagnosis to death. Cox proportional-hazards models were used for univariate and multivariate analyses. Results are expressed as hazard ratios (HRs) with 95% confidence intervals (95% CIs).
Additional statistical methods are delineated in supplementary Materials and Methods, available at Annals of Oncology online.
results
PD-L1 expression in melanoma tissues
PD-L1 expression was studied by IHC in 81 consecutive, well characterized MMP. PD-L1 expression was considered either as a continuous or discontinuous variable using the 5% published [16] or the 17.5% cutoff, determined here by recursive partitioning analysis (RPA), yielding comparable results.
In 73/81 MMP (90%), both ab58810 polyclonal (Abcam) and 5H1 monoclonal anti-PD-L1 antibodies were tested, showing a high concordance rate (Cohen's κ 72%, P < 0.0001). Representative examples of PD-L1 immunostaining in melanoma tissues are illustrated in Figure 1 The PD-L1 positivity barely correlated with BRAF mutation, although did not reach statistical significance (P = 0.051, supplementary Table S6 , available at Annals of Oncology online).
Lastly, PD-L1 mRNA levels did not correlate with membrane protein expression in 34 samples analyzed (Cohen's κ < 3%, P = 0.4273, supplementary Table S7 and Figure S5 , available at Annals of Oncology online), suggesting that protein expression must be used for diagnostic and prognostic purposes.
correlation between PD-L1 expression, DFS and OS DFS was not significantly different between PD-L1 + and PD-L1 − lesions (Figure 2A and B Table S8 , available at Annals of Oncology online).
At a median follow-up of 147 months, the median OS for the whole group of patients was 42 months. At the time of the analysis, 20 patients were still alive and 61 dead. At multivariate analysis, PD-L1 membrane positivity was an independent risk factors for melanoma-specific death [PD-L1 5% cutoff (HR 3.92, CI 95% 1.61-9.55, P < 0.003), PD-L1 as continuous variable (HR 1.03, CI 95% 1.01-1.05, P < 0.002), supplementary Tables S9 and S10, available at Annals of Oncology online, Figure 2C and D]. On the contrary, median OS did not differ in patients with cytoplasmic PD-L1
− versus PD-L1 + lesions (16 versus 12 months, respectively, P = 0.1130).
Finally, by multivariate analysis, Breslow thickness, but not ulceration, correlated with OS. Several reasons may justify these results including: (i) the relative small sample size, (ii) the subgroup comparisons, (iii) the influence of subsequent therapies on patient outcome.
Thirty-four patients received a BRAFi at some point after diagnosis of MM [25 treated with Vemurafenib (no restrictions on prior therapy), 9 with Dabrafenib ( patients had to have completed treatment or experienced treatment failure with at least one prior standard systemic therapy)]. In the subgroup of patients treated with BRAFi median OS was 16 months in PD-L1 − versus 9 in PD-L1 + melanomas (P = 0.0473). When OS was analyzed as the time from diagnosis of metastatic disease to death, membrane PD-L1 expression remained an independent prognostic factor as continuous variable or when a 5% cut off was considered (supplementary Table S11 , available at Annals of Oncology online).
These results suggest that PD-L1 membrane expression is an independent marker of unfavorable prognosis for MMP.
morphological features of PD-L1
+ versus PD-L1 −
A375 variants
In the second part of the work, we asked whether PD-L1 expression was simply the result of microenvironmental pressures on the tumor cell or whether it was an intrinsic feature, marking a disease subset with specific characteristics. After testing PD-L1 expression in a panel of melanoma cell lines, the A375 cell line emerged as the only one with a constitutive PD-L1 + subpopulation (supplementary Figure S6 , available at Annals of Oncology online).
A375 variants homogeneously PD-L1 + and PD-L1 − were stabilized from the parental BRAF-mutated A375 cell line by repeated cycles of immunomagnetic bead separation and cell sorting (supplementary Figure S7A , available at Annals of Oncology online).
PD-L1 + A375 cells grew loosely adherent to plastic and displayed an elongated shape, while the PD-L1
− variant was made of polygonal cells tightly adherent to plastic (supplementary Figure S7B , available at Annals of Oncology online). The PD-L1 These results suggest that PD-L1 expression defines a subset of A375 cells characterized by a fibroblast-like morphology and invasive properties. They also suggest that PD-L1 is a marker of a more activated status of the melanoma cell line and not mechanistically responsible for the observed phenotype.
PDL-1 + A375 cells show a distinct gene profile with upregulation of genes regulating tumor growth and diffusion
Global gene expression profiles of PD-L1 + and PD-L1 − A375 cells were then compared. In unsupervised hierarchical clustering analysis, the gene expression profiles of A375/PD-L1 + were clearly distinguishable from those of PD-L1
− replicates. The characteristics of the genetic signature of PD-L1 + cells are shown in Figure 3A and supplementary Table S12, available at Annals of Oncology online. The genes most differentially expressed by PD-L1 + cells are connected with activation/adhesion/movement pathways ( Figure 3A and B) .
In a supervised analysis, a number of differentially expressed genes connected with cell growth and invasion were selected. Relevant examples of upmodulated genes include integrin α3 (ITGA3) and caveolin 1 (CAV1, Figure 3C ). On the contrary, genes connected with antigen presentation and immune Figure 3C ). Flow cytometric analyses confirmed a marked downregulation in the expression of HLA Class II, CD74 and CD56 by PD-L1 + cells, while caveolin 1 protein was increased ( Figure 3D ). All integrin α subunits were significantly upregulated in A375 PD-L1 + variant, as confirmed by western blot ( Figure 3E ) and confocal microscopy ( Figure 3F 
PD-L1 + A375 cells show enhanced migration and invasion in vitro
The enrichment in the expression of genes connected to migration and invasion in PD-L1 + A375 cells was then functionally confirmed. Chemotaxis assays indicated that the PD-L1 + variant migrated in a significantly more efficient way than the PD-L1 Wound-healing assays confirmed that the PD-L1 + cells were able to migrate to the site of the wound with marked repair after 48 h, while the counterpart was significantly less efficient. As observed above, A375 WT cells displayed an intermediate ability to heal the wound ( Figure 4B ). PD-L1 INF cells were not significantly different from the WT counterpart (supplementary Figure S8E , available at Annals of Oncology online).
PD-L1 + A375 cells show enhanced growth and diffusion in vivo
The second set of genes that were up-regulated in the PD-L1 + A375 variant was connected to growth and activation. Consistently, PD-L1 + A375 cells grew more than PD-L1 − ones in 3D cultures. PD-L1 + cells were characterized by a constitutively higher degree of phosphorylation of the MAP kinases, including ERK1/2, p38 and JNK both in 2D ( Figure 4C ) and 3D cultures (supplementary Figure S11 , available at Annals of Oncology online).
By using a xenograft model, we could confirm the increased growth potential of PD-L1 + when compared with PD-L1 − A375 cells. In these experiments, cells were injected subcutaneously This study shows that PD-L1 is an independent negative prognostic factor in melanoma patients. This conclusion was reached upon testing PD-L1 expression in a cohort of 81 consecutive MMP treated at a single institution, and comparing two antibodies specific for PD-L1. In our series, the mouse monoclonal 5H1 antibody yielded the most reliable results. The second indication is that PD-L1 cytoplasmic staining is not suitable for prognostic purposes. The third indication is that PD-L1 mRNA levels are not predictive of protein expression, in agreement with previous studies [17] . The lack of correlation between PD-L1 mRNA levels and protein expression may be explained on the basis of two hypotheses: (i) PD-L1 expression is controlled by posttranscriptional mechanisms, (ii) proinflammatory stimuli such as IFN-γ, IL-4 and GM-CSF are potent activators for inducing B7-H1 protein expression [9, 11] .
In agreement with a negative prognostic role for PD-L1, our study shows that MM express PD-L1 in significantly higher proportions than primary lesions (40.3% versus 14%). In 17/22 patients, the metastatic site resulted positive while primary melanomas were negative, suggesting that PD-L1 expression is acquired during disease progression. PD-L1 expression has been reported as neither a fixed characteristic of tumor cells, nor homogeneously expressed. Hence, in 10 PD-L1 − patients multiple metastatic tumor samples from the same patient were analyzed, with concordant results. In two further PD-L1 − patients that were treated with a BRAFi, resistance acquisition was accompanied by a transition of the lesion from PD-L1
− to PD-L1 + . The second result of this work is that PD-L1 expression appears to correlate with shorter OS during BRAFi treatment. If confirmed in larger cohorts, this observation may be useful to better stratify patients within clinical trials.
The impact of PD-L1 expression in terms of clinical behavior was addressed by prior studies with controversial results, which may be attributed partly to the absence of a validated staining method and partly to the relatively small size of the cohorts studied. While our study used a relatively large cohort and a validated staining method, its main limitation is the retrospective nature, suggesting that these results should be confirmed with a prospective study.
The functional significance of PD-L1 expression is classically attributed to the inhibition of T cell responses, obtained through binding of the PD-1 receptor [11] . Consistently, a recent paper reported a positive correlation between PD-L1 expression by melanocytes and lymphocyte infiltration in both nevi and melanomas, with PD-L1 + melanocytes, being frequently adjacent to infiltrating lymphocytes [12] . In our series and in an additional independent cohort of 17 primary melanoma samples, no significant association was observed between PD-L1 expression and the degree of TILs. It should be noted that, in our series, most of patients received chemotherapy or BRAFi while in the study reported by Taube et al. patients were receiving immunotherapy [12] . This suggests that the type of treatment received should be considered when correlating PD-L1 expression with survival outcomes.
Nevertheless, the functional significance of constitutive and targeted therapy-modulated PD-L1 expression has not been entirely elucidated. A recent study evaluating PD-L1 expression in a large panel of melanoma cell lines with or without exposure to MAPK inhibitors showed that there is no association between MAPK/PI3 K activation and PD-L1 expression, suggesting that the constitutive PD-L1 expression or PD-L1 expression upon alterations of signaling pathways, in the absence of a T-cell infiltration, may not serve as a biomarker [18] .
Besides its role as an immunomodulatory molecule, recent data in ovarian tumor models suggest that PD-L1 might per se determine a more aggressive clinical course [19, 20] . To clarify whether this may be confirmed in melanoma models, in the second part of the paper, we explored the functional significance of PD-L1 expression by melanoma cells. To do so, we used the A375 line, which constitutively presents distinct PD-L1 + and a PD-L1 − subpopulations, a unique situation in the melanoma lines tested. Stable PD-L1 + and PD-L1 − variants of the A375 cell line were thus stabilized and comparatively studied. Gene profiling indicated that the PD-L1 + cell subset is characterized by a unique genetic signature, with enhanced expression of genes connected to growth, activation and invasion. A functional comparison confirmed that: (i) the PD-L1 + variant showed signs of increased growth and invasion in vitro, (ii) these features were enhanced when using 3D cultures and maintained after xenografting in immunocompromised mice. Forced expression of PD-L1 molecules in the PD-L1-variant of the A375 line, however, was not followed by the acquisition of increased growth and motility properties. This observation suggests that PD-L1 expression might be a downstream marker of the activation of an oncogenic pathway characterizing a genetically different cell subset, which shows enrichment in genes that control cell differentiation and movement. It also argues against a mechanistic involvement of PD-L1 in determining increased aggressiveness of the disease.
In conclusion, from the clinical standpoint, the present results suggest PD-L1 expression as a negative prognostic factor in melanoma patients. From the translational standpoint, they indicate that beside the known effects on immune response modulation, PD-L1 expression marks a subset of melanoma cells characterized by a specific gene expression profile and by increased growth and aggressiveness. Our results suggest that PD-L1 is not mechanistically responsible for the more aggressive phenotype in melanoma cells. Future studies will tell whether PD-L1 expression is also a marker of resistance to selected therapies and whether it may be successfully exploited alone or in combination as a target for specific subsets of melanoma patients. 
